William H. Lewis is the Chief Executive Officer of Insmed Incorporated (INSMED INC), a global biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases. With a career spanning several decades in the biopharmaceutical industry, Lewis has held numerous leadership positions that have contributed to his expertise in driving the growth and success of life sciences organizations. Before joining Insmed in 2012 as President and Chief Executive Officer, Lewis served as Senior Vice President and Chief Financial Officer at Aegerion Pharmaceuticals, where he played a pivotal role in the company's successful IPO and the development of its first commercial product. Prior to Aegerion, he held various executive positions at companies such as Genzyme Corporation, where he was instrumental in the growth of the company's rare disease portfolio. Lewis's strategic vision and financial acumen have been crucial in guiding Insmed through significant milestones, such as the approval and launch of ARIKAYCE®, the company's first commercial product for the treatment of a rare lung disease. Under Lewis's leadership, Insmed has expanded its pipeline and global presence, focusing on addressing the unmet medical needs of patients with rare diseases. His commitment to innovation and patient-centricity has fostered a culture of excellence within the organization. Lewis holds a Bachelor of Science degree in Business Administration from the University of Richmond and an MBA from the Darden School of Business at the University of Virginia, further solidifying his strong foundation in business and strategic management.